Want to see UPB full AI Analyst Report?
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.85 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)639.22K
Market Cap
$408.69M
Enterprise Value$239.07M
Total Cash (Recent Filing)$294.58M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding54,419,987
10 Day Avg. Volume754,286
30 Day Avg. Volume639,216
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue71.97
Enterprise Value/Gross Profit73.04
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$42.33Price Target Upside39.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.87
Revenue Forecast (FY)$2.18M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetDebt minimal relative to equity gives durable financial flexibility for a clinical-stage biotech. Low leverage reduces refinancing and interest risks, supporting continued R&D spending, licensing optionality, or strategic partnerships without immediate pressure to cut programs.
Modest Revenue Growth With Strong Gross MarginsConsistent top-line expansion and a ~66% gross margin indicate scalable product economics once candidates advance. For a development-stage company, growing revenue plus high gross margins suggest capacity to improve operating leverage as programs mature or partner revenues recur.
Governance Continuity And Auditor RatificationRe-affirmation of board nominees and PwC oversight provides governance stability and audit continuity. For a clinical-stage firm, steady governance reduces execution risk, aids credibility in partnering or capital-raising, and supports consistent compliance during complex trials.
Bears Say
Accelerating Cash BurnWorsening negative operating and free cash flow is a durable constraint: sustained burn shortens runway and forces reliance on equity raises, licensing deals, or partnering. That dynamic can dilute shareholders, shift strategic priorities, or delay programs if funding terms tighten.
Deep, Persistent Losses And Margin DeteriorationLarge operating and net losses that are widening indicate structural expense growth outpacing revenue. For a clinical-stage biotech, sustained negative profitability increases dependence on external capital and may pressure program prioritization, slowing long-term value creation.
Negative Returns On Equity / Poor Capital EfficiencySharply negative ROE shows the sizable equity base is not generating returns, reflecting low capital efficiency. Over months this can limit investor confidence, complicate future funding, and suggest that additional capital injections may not translate into proportionate value creation.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.85 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $408.69M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on May 13, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.02.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.74.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,419,987 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 4.581%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (39.71% Upside)
$42.33 (39.71% Upside)
Blogger Sentiment
Bullish
UPB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.52%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
-30.28%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
UPB Stock 12 Month Forecast
Average Price Target
$42.33
▲(39.71% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.69% Insiders
21.75% Mutual Funds
34.74% Other Institutional Investors
25.96% Public Companies and
Individual Investors